Braveheart Bio (BRVE) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zenas BioPharma is the larger company by market cap ($1.67 billion vs $1.61 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | ZBIO |
|---|---|---|
| Share price | $17.93 | $25.64 |
| Market cap | $1.61B | $1.67B |
| 1-day change | -3.50% | -9.01% |
| YTD return | — | -22.39% |
| 1-year return | — | +35.16% |
| EPS (TTM) | $-6.08 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $32.00 | $44.60 |
| 52-week low | $17.86 | $13.50 |
| Distance from 52-week high | -43.97% | -42.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +152.37% | +86.74% |
| Average volume | 562.23K | 735.12K |
| Shares outstanding | 90.04M | 65.18M |
| Employees | 49 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
BRVE vs ZBIO FAQ
Which is bigger, Braveheart Bio or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.67B compared with $1.61B for Braveheart Bio (BRVE).
Are Braveheart Bio and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.